Pyxis Oncology (PYXS) Non-Current Deferred Tax Liability (2022 - 2024)
Pyxis Oncology (PYXS) posted quarterly Non-Current Deferred Tax Liability of $2.2 million for Q3 2024, little changed quarter-over-quarter from $2.2 million in Q2 2024.
Pyxis Oncology (PYXS) Non-Current Deferred Tax Liability (2022 - 2024) Analysis & Trends
Pyxis Oncology (PYXS) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $2.2 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $2.2 million; the TTM figure through Sep 2024 stood at $2.2 million (changed N/A YoY), while the FY2023 annual figure was $2.2 million, down 41.1% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $2.2 million in Q3 2024 per PYXS's latest filing, from $2.2 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.7 million in Q4 2022 and bottomed at $2.2 million in Q4 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $2.5 million across 3 years, with a median of $2.2 million in 2023.
- On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 41.1% in 2023 and fell as far as 41.1% in 2023.
- Pyxis Oncology's Non-Current Deferred Tax Liability stood at $3.7 million in 2022, then slumped by 41.1% to $2.2 million in 2023, then changed by 0.0% to $2.2 million in 2024.
- Business Quant data shows PYXS's Non-Current Deferred Tax Liability at $2.2 million in Q3 2024, $2.2 million in Q2 2024, and $2.2 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.16 Mn |
| Dec 31, 2023 | 2.16 Mn |
| Dec 31, 2022 | 3.67 Mn |
| Dec 31, 2022 | 3.67 Mn |